MAXION THERAPEUTICS
Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
• Investor syndicate comprised of LifeArc Ventures, Monograph Capital and BGF
• Funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class